Trial Profile
Effects of switching from tenofovir/emtricitabin to abacavir/lamivudine and vice versa on platelet aggregation and coagulation markers in patients with HIV-1 infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir (Primary) ; Lamivudine/abacavir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms TAPAS
- 17 Oct 2016 New trial record